Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.
You may also be interested in...
Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint
New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.
Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle
The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.